ClinicalTrials.gg
CompletedNCT02832375Updated May 25, 2017Results posted

Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity

A Phase 3 interventional study of stannous fluoride and sodium monofluorophosphate in Dentin Sensitivity, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-25.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Dentin Sensitivity by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Dentin Sensitivity · GlaxoSmithKline.

Enrollment
5th of 28
242 · median 164
Started
2016
with 11 others
Phase 3
5 of 28
none open now
Registered
13th of 28
by date

Among the 28 studies in Dentin Sensitivity by GlaxoSmithKline, this one is the 5th largest by enrollment, is one of 12 that started in 2016, is one of 5 in phase 3, and was the 13th registered.

Dentin Sensitivity

290 studies on the registry are indexed under Dentin Sensitivity; 48 are open to participants now.

Browse Dentin Sensitivity studies →

Open to participants now

None of the 28 studies in Dentin Sensitivity by GlaxoSmithKline is open now. The open studies under Dentin Sensitivity, anywhere →

Who these studies take

Of the 19 Dentin Sensitivity studies recruiting now, 6 (32%) set no upper age limit and 12 (63%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies in Dentin Sensitivity by GlaxoSmithKline as a file.
02

Study summary

This single center, comparative design study will be used to investigate the efficacy of an experimental stannous fluoride containing dentifrice in relieving dentinal hypersensitivity (DH) after short term use compared with a standard fluoride dentifrice.

Read the detailed description

This will be a single center, three day, randomized, examiner blind, two treatment arm, parallel design, stratified (by maximum baseline Schiff sensitivity score of the two selected test teeth), controlled study, in participants with at least two sensitive teeth that meet all the criteria at the screening and baseline (pre-treatment) visits. DH will be assessed at baseline (pre-treatment), post-treatment and after 3 days twice daily brushing.

03

Conditions studied

  • Dentin Sensitivity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written and has received a signed and dated copy of the informed consent form.
  • Aged 18-65 years inclusive
  • Understands and is willing, able and likely to comply with all study procedures and restrictions
  • Good general and mental health with, in the opinion of the investigator or medically qualified designee: No , relevant abnormalities of medical history or oral examination and Absence of any condition that would impact on the participant's safety or wellbeing or affect the individual's ability to understand and follow study procedures and requirements
  • Self-reported history of DH lasting more than six months but not more than 10 years at screening
  • Minimum of 20 natural teeth at screening
  • Minimum of 2 accessible non-adjacent teeth (incisors, canines, pre-molars), preferably in different quadrants that meet all of the following criteria: Signs of facial/cervical gingival recession and/or signs of erosion or abrasion (EAR) Tooth with MGI score =0 adjacent to the test area (exposed dentine) only and a clinical mobility of less than or equal to (≤)1 and Tooth with signs of sensitivity measured by qualifying evaporative air assessment (Y[Yes]/N[No] response) screening
  • Minimum of two, non-adjacent accessible teeth (incisors, canines, pre-molars),that meet all of the following criteria at Baseline: Tooth with signs of sensitivity, measured by qualifying tactile stimulus (Yeaple ≤ 20g) and evaporative air assessment (Schiff sensitivity score ≥ 2)

Exclusion criteria

Exclusion Criteria:

  • Women who are known to be pregnant. Females of child bearing potential who have a positive urine pregnancy test or who are breast feeding
  • Known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients
  • Previous participation in this study or participation in another clinical study (including cosmetic studies) or receipt of an drug within 30 days of the screening visit
  • Recent history (within the last year) of alcohol or other substance abuse
  • An employee of the sponsor or the study site or members of their immediate family
  • Presence of chronic debilitating disease which, in the opinion of the investigator, could affect study outcomes or Any condition which, in the opinion of the investigator, causes xerostomia
  • Dental prophylaxis within 4 weeks of Screening, tongue or lip piercing or presence of dental implants, gross periodontal disease, treatment of periodontal disease (including surgery) within 12 months of Screening, scaling or root planning within 3 months of Screening and teeth bleaching within 8 weeks of Screening
  • Tooth with evidence of current or recent caries, or reported treatment of decay within 12 months of Screening
  • Tooth with exposed dentine but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns or veneers, orthodontic bands or cracked enamel. Sensitive teeth with contributing aetiologies other than erosion, abrasion or recession of exposed dentine
  • Sensitive tooth not expected to respond to treatment with an over-the-counter dentifrice in the opinion of the Investigator
  • Use of an oral care product indicated for the relief of dentine hypersensitivity within 8 weeks of screening
  • Daily doses of medication/treatments which, in the opinion of the investigator, could interfere with the perception of pain. Examples of such medications include analgesics, anticonvulsants, antihistamines that cause marked or moderate sedation, sedatives, tranquilizers, anti-depressants, mood-altering and anti-inflammatory drugs.
  • Currently taking antibiotics or has taken antibiotics within 2 weeks of Baseline, Daily dose of a medication which, in the opinion of the investigator, is causing xerostomia
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    Experimental: stannous fluoride

    Participants will be instructed to dose a dry toothbrush containing 0.454% w/w of stannous fluoride (1000 parts per million \[ppm\] fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.

    Drug: stannous fluoride

  • Active comparator
    Standard: sodium monofluorophosphate

    Participants will be instructed to dose a dry toothbrush containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.

    Drug: sodium monofluorophosphate

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Schiff Sensitivity Score on Day 3

    Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.

    Time frame: Baseline, Day 3

Secondary outcomes

  1. Change From Baseline in Schiff Sensitivity Score After Single Use

    Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.

    Time frame: Baseline, after single use (after 5 minutes)

  2. Change From Baseline in Tactile Threshold Immediately After Single Use and on Day 3

    Tactile threshold was assessed by examiner using a constant pressure probe (Yeaple probe) which allowed application of a known force to the dentin surface from 10 g to an upper threshold of 80g in increments of 10 g. The tactile threshold is the maximum pressure applied at which participant do not report any pain or discomfort. The tactile threshold for each tooth was determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth.

    Time frame: Baseline, after single use (after 5 minutes) and on Day 3

07

Results

Posted Feb 27, 2017

Participant flow

Participants were recruited at one center in United States.

Participant flow — Overall Study
MilestoneExperimental: Stannous Fluoride(SnF)Control: Sodium Monofluorophosphate(SMFP)
Started121121
Completed119121
Not completed20
Withdrew: Lost to follow-up10
Withdrew: Withdrawal of consent10

Outcome measures

PrimaryChange From Baseline in Schiff Sensitivity Score on Day 3

Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.

Time frame:
Baseline, Day 3
Reported as:
Mean · score on a scale
Change From Baseline in Schiff Sensitivity Score on Day 3
score on a scaleExperimental: Stannous Fluoride(SnF)Control: Sodium Monofluorophosphate(SMFP)
Change From Baseline in Schiff Sensitivity Score on Day 3-0.82 ± 0.644-0.39 ± 0.426
Statistical analysis
  • Experimental: Stannous Fluoride(SnF) vs Control: Sodium Monofluorophosphate(SMFP) · ANCOVA · p = <0.0001 · Least square (ls) mean difference: -0.45 · 95% CI -0.577 to -0.319Difference is first named dentifrice minus second named dentifrice such that a negative difference favours first named dentifrice.
SecondaryChange From Baseline in Schiff Sensitivity Score After Single Use

Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.

Time frame:
Baseline, after single use (after 5 minutes)
Reported as:
Mean · score on a scale
Change From Baseline in Schiff Sensitivity Score After Single Use
score on a scaleExperimental: Stannous Fluoride(SnF)Standard: Sodium Monofluorophosphate(SMFP)
Change From Baseline in Schiff Sensitivity Score After Single Use-0.46 ± 0.507-0.45 ± 0.465
SecondaryChange From Baseline in Tactile Threshold Immediately After Single Use and on Day 3

Tactile threshold was assessed by examiner using a constant pressure probe (Yeaple probe) which allowed application of a known force to the dentin surface from 10 g to an upper threshold of 80g in increments of 10 g. The tactile threshold is the maximum pressure applied at which participant do not report any pain or discomfort. The tactile threshold for each tooth was determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth.

Time frame:
Baseline, after single use (after 5 minutes) and on Day 3
Reported as:
Mean · g
Change From Baseline in Tactile Threshold Immediately After Single Use and on Day 3
gExperimental: Stannous Fluoride(SnF)Standard: Sodium Monofluorophosphate(SMFP)
Change from baseline post treatment4.01 ± 7.5453.60 ± 7.252
Change from baseline on Day 315.25 ± 17.7663.88 ± 6.785

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Stannous Fluoride(SnF)0/121 (0%)0/121 (0%)1/121 (0.8%)
Standard: Sodium Monofluorophosphate(SMFP)0/121 (0%)0/121 (0%)2/121 (1.7%)
Most frequent other events
Most frequent other events
EventExperimental: Stannous Fluoride(SnF)Standard: Sodium Monofluorophosphate(SMFP)
Oral Mucosal ExfoliationGastrointestinal disorders1/1210/121
Leukoplakia OralGastrointestinal disorders0/1211/121
Lip UlcerationGastrointestinal disorders0/1211/121

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Experimental: Stannous Fluoride(SnF)Control: Sodium Monofluorophosphate(SMFP)Total
Mean38.0 ± 11.3237.4 ± 11.0137.7 ± 11.15
Sex: Female, Male
Sex: Female, Male(Participants)Experimental: Stannous Fluoride(SnF)Control: Sodium Monofluorophosphate(SMFP)Total
Female7678154
Male454388
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental: Stannous Fluoride(SnF)Control: Sodium Monofluorophosphate(SMFP)Total
Hispanic or Latino271946
Not Hispanic or Latino94102196
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental: Stannous Fluoride(SnF)Control: Sodium Monofluorophosphate(SMFP)Total
American Indian or Alaska Native112
Asian91019
Native Hawaiian or Other Pacific Islander437
Black or African American252752
White7472146
More than one race8816
Unknown or Not Reported000
Shiff Sensitivity Score at Baseline
Shiff Sensitivity Score at Baseline(score on a scale)Experimental: Stannous Fluoride(SnF)Control: Sodium Monofluorophosphate(SMFP)Total
Mean2.53 ± 0.3892.55 ± 0.3972.54 ± 0.392
Tactile Threshold at Baseline
Tactile Threshold at Baseline(gram (g))Experimental: Stannous Fluoride(SnF)Control: Sodium Monofluorophosphate(SMFP)Total
Mean10.00 ± 0.00010.00 ± 0.00010.00 ± 0.000
08

Study locations

1 site
  • GSK Investigational Site
    Las Vegas, Nevada 89146, United States
09

References and documents

Publications

  • Creeth J, Gallob J, Sufi F, Qaqish J, Gomez-Pereira P, Budhawant C, Goyal C. Randomised clinical studies investigating immediate and short-term efficacy of an occluding toothpaste in providing dentine hypersensitivity relief. BMC Oral Health. 2019 Jun 4;19(1):98. doi: 10.1186/s12903-019-0781-x. PubMed 31164116 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2016
First posted
Jul 14, 2016
Start
Mar 1, 2016
Primary completionActual
May 1, 2016
CompletionActual
May 12, 2016
Results first posted
Feb 27, 2017
Last update
May 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02832375
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 14, 2016
Start date
Mar 1, 2016
Primary completion
May 1, 2016
Completion
May 12, 2016
Results posted
Feb 27, 2017
Last update
May 25, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tin Fluorides

Start the discussion